Expression of SOX2OT in 118 surgical specimens from glioma patients who were receiving TMZ chemotherapy (Supplementary Table S1) showed that SOX2OT level was positively associated with tumor grading (WHO I/II versus WHO III/IV) (p < 0.001), confirmed by qRT-PCR analysis (Fig. 1g). The gene discussed is SOX2-OT; the disease is neoplasm.